Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study.
Identifieur interne : 000210 ( Main/Exploration ); précédent : 000209; suivant : 000211Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study.
Auteurs : Rosemary Markovic Delabre [France] ; Nicolas Salez [France] ; Magali Lemaitre [France] ; Marianne Leruez-Ville [France] ; Xavier De Lamballerie [France] ; Fabrice Carrat [France]Source :
- Vaccine [ 1873-2518 ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Anticorps antiviraux (sang), Femelle (MeSH), France (MeSH), Grippe humaine (immunologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Protection croisée (MeSH), Sous-type H1N1 du virus de la grippe A (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Tests d'inhibition de l'hémagglutination (MeSH), Études de cohortes (MeSH).
- MESH :
- immunologie : Grippe humaine.
- sang : Anticorps antiviraux.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, France, Humains, Jeune adulte, Mâle, Protection croisée, Sous-type H1N1 du virus de la grippe A, Sujet âgé, Sujet âgé de 80 ans ou plus, Tests d'inhibition de l'hémagglutination, Études de cohortes.
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antibodies, Viral (blood), Cohort Studies (MeSH), Cross Protection (MeSH), Female (MeSH), France (MeSH), Hemagglutination Inhibition Tests (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (MeSH), Influenza, Human (immunology), Male (MeSH), Middle Aged (MeSH), Young Adult (MeSH).
- MESH :
- chemical , blood : Antibodies, Viral.
- geographic : France.
- immunology : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Cohort Studies, Cross Protection, Female, Hemagglutination Inhibition Tests, Humans, Influenza A Virus, H1N1 Subtype, Male, Middle Aged, Young Adult.
Abstract
INTRODUCTION
Haemagglutination-inhibition (HI) antibody titer is a correlate of protection against influenza; its persistence after infection or vaccination is important to determining susceptibility to subsequent infection. Few studies, however, have reported longitudinal data regarding the magnitude and duration of HI protection following natural seasonal influenza A infection.
METHODS
Using French influenza cohort study data collected from 2008 to 2010, we investigated persistence of serological protection among subjects according to influenza-like illness (ILI) and laboratory-confirmed seasonal 2007 influenza A(H1N1) infection status at inclusion in 2008 (ILI-A(H1N1) positive, ILI-A(H1N1) negative, or no-ILI). Antibody titers against seasonal 2007 A(H1N1) were determined using the HI technique for sera. Regression models for interval-censored data were used to estimate geometric mean titers (GMT) for HI assays. A logistic regression model adjusted for age group (subjects <30, 30-50 and >50 years old) was used to quantify the association between HI titer and protection against infection.
RESULTS
Based on 310 total subjects, influenza A(H1N1) infection was confirmed in 39 of 115 ILI subjects at inclusion. GMT associated with 50% probability of protection among ILI subjects decreased with age group (subjects <30 yo: GMT of 40.8 was associated with 50% [95CI: 29.3%; 70.7%] probability of protection, subjects 30-50 yo: 26.8 [95CI: 34.4%; 65.6%] and subjects >50 yo: 8.9 [95CI: 15.3%; 84.7%]). GMT declined after the first annual study visit among ILI-A(H1N1) positive subjects but remained higher compared to inclusion at the 2010 study visit (41.5 [95CI: 34.8; 49.5], p=0.0157). GMT remained stable among ILI-A(H1N1) negative subjects (p=0.7502), but decreased among no-ILI subjects (p<0.0001).
CONCLUSION
Our results confirm the positive relationship between HI titer and probability of protection among naturally infected subjects, and provides evidence that protection associated with HI titer varies with age. This longitudinal analysis suggests the rise in HI titers following seasonal 2007 influenza A(H1N1) infection may persist into subsequent influenza seasons.
DOI: 10.1016/j.vaccine.2015.09.016
PubMed: 26387434
Affiliations:
- France
- Provence-Alpes-Côte d'Azur, Région Bretagne, Île-de-France
- Marseille, Paris, Rennes
- Université Paris-Descartes
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study.</title><author><name sortKey="Delabre, Rosemary Markovic" sort="Delabre, Rosemary Markovic" uniqKey="Delabre R" first="Rosemary Markovic" last="Delabre">Rosemary Markovic Delabre</name><affiliation wicri:level="3"><nlm:affiliation>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France. Electronic address: rosemary.delabre@iplesp.upmc.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Salez, Nicolas" sort="Salez, Nicolas" uniqKey="Salez N" first="Nicolas" last="Salez">Nicolas Salez</name><affiliation wicri:level="3"><nlm:affiliation>Emergence des Pathologies Virales, UMR_D 190, Aix-Marseille Université and Institut de Recherche pour le Développement, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Emergence des Pathologies Virales, UMR_D 190, Aix-Marseille Université and Institut de Recherche pour le Développement, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Lemaitre, Magali" sort="Lemaitre, Magali" uniqKey="Lemaitre M" first="Magali" last="Lemaitre">Magali Lemaitre</name><affiliation wicri:level="1"><nlm:affiliation>National Agency for the Safety of Medicine and Health Products, St Denis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>National Agency for the Safety of Medicine and Health Products, St Denis</wicri:regionArea><wicri:noRegion>St Denis</wicri:noRegion><wicri:noRegion>St Denis</wicri:noRegion></affiliation></author><author><name sortKey="Leruez Ville, Marianne" sort="Leruez Ville, Marianne" uniqKey="Leruez Ville M" first="Marianne" last="Leruez-Ville">Marianne Leruez-Ville</name><affiliation wicri:level="4"><nlm:affiliation>Université Paris Descartes, Sorbonne Paris Cité, EA 7328 Paris, France; Laboratoire de Virologie, Hôpital Necker, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris Descartes, Sorbonne Paris Cité, EA 7328 Paris, France; Laboratoire de Virologie, Hôpital Necker, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation></author><author><name sortKey="De Lamballerie, Xavier" sort="De Lamballerie, Xavier" uniqKey="De Lamballerie X" first="Xavier" last="De Lamballerie">Xavier De Lamballerie</name><affiliation wicri:level="3"><nlm:affiliation>Emergence des Pathologies Virales, UMR_D 190, Aix-Marseille Université and Institut de Recherche pour le Développement, Marseille, France; IHU Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Ecole des Hautes Etudes en Santé Publique, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Emergence des Pathologies Virales, UMR_D 190, Aix-Marseille Université and Institut de Recherche pour le Développement, Marseille, France; IHU Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Ecole des Hautes Etudes en Santé Publique, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Carrat, Fabrice" sort="Carrat, Fabrice" uniqKey="Carrat F" first="Fabrice" last="Carrat">Fabrice Carrat</name><affiliation wicri:level="3"><nlm:affiliation>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France; Unité de Santé Publique, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France; Unité de Santé Publique, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26387434</idno><idno type="pmid">26387434</idno><idno type="doi">10.1016/j.vaccine.2015.09.016</idno><idno type="wicri:Area/Main/Corpus">000182</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000182</idno><idno type="wicri:Area/Main/Curation">000182</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000182</idno><idno type="wicri:Area/Main/Exploration">000182</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study.</title><author><name sortKey="Delabre, Rosemary Markovic" sort="Delabre, Rosemary Markovic" uniqKey="Delabre R" first="Rosemary Markovic" last="Delabre">Rosemary Markovic Delabre</name><affiliation wicri:level="3"><nlm:affiliation>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France. Electronic address: rosemary.delabre@iplesp.upmc.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Salez, Nicolas" sort="Salez, Nicolas" uniqKey="Salez N" first="Nicolas" last="Salez">Nicolas Salez</name><affiliation wicri:level="3"><nlm:affiliation>Emergence des Pathologies Virales, UMR_D 190, Aix-Marseille Université and Institut de Recherche pour le Développement, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Emergence des Pathologies Virales, UMR_D 190, Aix-Marseille Université and Institut de Recherche pour le Développement, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Lemaitre, Magali" sort="Lemaitre, Magali" uniqKey="Lemaitre M" first="Magali" last="Lemaitre">Magali Lemaitre</name><affiliation wicri:level="1"><nlm:affiliation>National Agency for the Safety of Medicine and Health Products, St Denis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>National Agency for the Safety of Medicine and Health Products, St Denis</wicri:regionArea><wicri:noRegion>St Denis</wicri:noRegion><wicri:noRegion>St Denis</wicri:noRegion></affiliation></author><author><name sortKey="Leruez Ville, Marianne" sort="Leruez Ville, Marianne" uniqKey="Leruez Ville M" first="Marianne" last="Leruez-Ville">Marianne Leruez-Ville</name><affiliation wicri:level="4"><nlm:affiliation>Université Paris Descartes, Sorbonne Paris Cité, EA 7328 Paris, France; Laboratoire de Virologie, Hôpital Necker, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris Descartes, Sorbonne Paris Cité, EA 7328 Paris, France; Laboratoire de Virologie, Hôpital Necker, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation></author><author><name sortKey="De Lamballerie, Xavier" sort="De Lamballerie, Xavier" uniqKey="De Lamballerie X" first="Xavier" last="De Lamballerie">Xavier De Lamballerie</name><affiliation wicri:level="3"><nlm:affiliation>Emergence des Pathologies Virales, UMR_D 190, Aix-Marseille Université and Institut de Recherche pour le Développement, Marseille, France; IHU Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Ecole des Hautes Etudes en Santé Publique, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Emergence des Pathologies Virales, UMR_D 190, Aix-Marseille Université and Institut de Recherche pour le Développement, Marseille, France; IHU Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Ecole des Hautes Etudes en Santé Publique, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Carrat, Fabrice" sort="Carrat, Fabrice" uniqKey="Carrat F" first="Fabrice" last="Carrat">Fabrice Carrat</name><affiliation wicri:level="3"><nlm:affiliation>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France; Unité de Santé Publique, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France; Unité de Santé Publique, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antibodies, Viral (blood)</term><term>Cohort Studies (MeSH)</term><term>Cross Protection (MeSH)</term><term>Female (MeSH)</term><term>France (MeSH)</term><term>Hemagglutination Inhibition Tests (MeSH)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (MeSH)</term><term>Influenza, Human (immunology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Anticorps antiviraux (sang)</term><term>Femelle (MeSH)</term><term>France (MeSH)</term><term>Grippe humaine (immunologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Protection croisée (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Tests d'inhibition de l'hémagglutination (MeSH)</term><term>Études de cohortes (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Cross Protection</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>France</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Protection croisée</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tests d'inhibition de l'hémagglutination</term><term>Études de cohortes</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>Haemagglutination-inhibition (HI) antibody titer is a correlate of protection against influenza; its persistence after infection or vaccination is important to determining susceptibility to subsequent infection. Few studies, however, have reported longitudinal data regarding the magnitude and duration of HI protection following natural seasonal influenza A infection.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Using French influenza cohort study data collected from 2008 to 2010, we investigated persistence of serological protection among subjects according to influenza-like illness (ILI) and laboratory-confirmed seasonal 2007 influenza A(H1N1) infection status at inclusion in 2008 (ILI-A(H1N1) positive, ILI-A(H1N1) negative, or no-ILI). Antibody titers against seasonal 2007 A(H1N1) were determined using the HI technique for sera. Regression models for interval-censored data were used to estimate geometric mean titers (GMT) for HI assays. A logistic regression model adjusted for age group (subjects <30, 30-50 and >50 years old) was used to quantify the association between HI titer and protection against infection.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Based on 310 total subjects, influenza A(H1N1) infection was confirmed in 39 of 115 ILI subjects at inclusion. GMT associated with 50% probability of protection among ILI subjects decreased with age group (subjects <30 yo: GMT of 40.8 was associated with 50% [95CI: 29.3%; 70.7%] probability of protection, subjects 30-50 yo: 26.8 [95CI: 34.4%; 65.6%] and subjects >50 yo: 8.9 [95CI: 15.3%; 84.7%]). GMT declined after the first annual study visit among ILI-A(H1N1) positive subjects but remained higher compared to inclusion at the 2010 study visit (41.5 [95CI: 34.8; 49.5], p=0.0157). GMT remained stable among ILI-A(H1N1) negative subjects (p=0.7502), but decreased among no-ILI subjects (p<0.0001).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Our results confirm the positive relationship between HI titer and probability of protection among naturally infected subjects, and provides evidence that protection associated with HI titer varies with age. This longitudinal analysis suggests the rise in HI titers following seasonal 2007 influenza A(H1N1) infection may persist into subsequent influenza seasons.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26387434</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>49</Issue><PubDate><Year>2015</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study.</ArticleTitle><Pagination><MedlinePgn>7015-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2015.09.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(15)01274-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Haemagglutination-inhibition (HI) antibody titer is a correlate of protection against influenza; its persistence after infection or vaccination is important to determining susceptibility to subsequent infection. Few studies, however, have reported longitudinal data regarding the magnitude and duration of HI protection following natural seasonal influenza A infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using French influenza cohort study data collected from 2008 to 2010, we investigated persistence of serological protection among subjects according to influenza-like illness (ILI) and laboratory-confirmed seasonal 2007 influenza A(H1N1) infection status at inclusion in 2008 (ILI-A(H1N1) positive, ILI-A(H1N1) negative, or no-ILI). Antibody titers against seasonal 2007 A(H1N1) were determined using the HI technique for sera. Regression models for interval-censored data were used to estimate geometric mean titers (GMT) for HI assays. A logistic regression model adjusted for age group (subjects <30, 30-50 and >50 years old) was used to quantify the association between HI titer and protection against infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Based on 310 total subjects, influenza A(H1N1) infection was confirmed in 39 of 115 ILI subjects at inclusion. GMT associated with 50% probability of protection among ILI subjects decreased with age group (subjects <30 yo: GMT of 40.8 was associated with 50% [95CI: 29.3%; 70.7%] probability of protection, subjects 30-50 yo: 26.8 [95CI: 34.4%; 65.6%] and subjects >50 yo: 8.9 [95CI: 15.3%; 84.7%]). GMT declined after the first annual study visit among ILI-A(H1N1) positive subjects but remained higher compared to inclusion at the 2010 study visit (41.5 [95CI: 34.8; 49.5], p=0.0157). GMT remained stable among ILI-A(H1N1) negative subjects (p=0.7502), but decreased among no-ILI subjects (p<0.0001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results confirm the positive relationship between HI titer and probability of protection among naturally infected subjects, and provides evidence that protection associated with HI titer varies with age. This longitudinal analysis suggests the rise in HI titers following seasonal 2007 influenza A(H1N1) infection may persist into subsequent influenza seasons.</AbstractText><CopyrightInformation>Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delabre</LastName><ForeName>Rosemary Markovic</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France. Electronic address: rosemary.delabre@iplesp.upmc.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salez</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Emergence des Pathologies Virales, UMR_D 190, Aix-Marseille Université and Institut de Recherche pour le Développement, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemaitre</LastName><ForeName>Magali</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Agency for the Safety of Medicine and Health Products, St Denis, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leruez-Ville</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Université Paris Descartes, Sorbonne Paris Cité, EA 7328 Paris, France; Laboratoire de Virologie, Hôpital Necker, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lamballerie</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Emergence des Pathologies Virales, UMR_D 190, Aix-Marseille Université and Institut de Recherche pour le Développement, Marseille, France; IHU Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Ecole des Hautes Etudes en Santé Publique, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrat</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France; Unité de Santé Publique, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056738" MajorTopicYN="Y">Cross Protection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibody</Keyword><Keyword MajorTopicYN="N">Cohort studies</Keyword><Keyword MajorTopicYN="N">Correlate</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="N">Influenza A virus, H1N1 subtype</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>02</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26387434</ArticleId><ArticleId IdType="pii">S0264-410X(15)01274-8</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2015.09.016</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li><li>Région Bretagne</li><li>Île-de-France</li></region><settlement><li>Marseille</li><li>Paris</li><li>Rennes</li></settlement><orgName><li>Université Paris-Descartes</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Delabre, Rosemary Markovic" sort="Delabre, Rosemary Markovic" uniqKey="Delabre R" first="Rosemary Markovic" last="Delabre">Rosemary Markovic Delabre</name></region><name sortKey="Carrat, Fabrice" sort="Carrat, Fabrice" uniqKey="Carrat F" first="Fabrice" last="Carrat">Fabrice Carrat</name><name sortKey="De Lamballerie, Xavier" sort="De Lamballerie, Xavier" uniqKey="De Lamballerie X" first="Xavier" last="De Lamballerie">Xavier De Lamballerie</name><name sortKey="Lemaitre, Magali" sort="Lemaitre, Magali" uniqKey="Lemaitre M" first="Magali" last="Lemaitre">Magali Lemaitre</name><name sortKey="Leruez Ville, Marianne" sort="Leruez Ville, Marianne" uniqKey="Leruez Ville M" first="Marianne" last="Leruez-Ville">Marianne Leruez-Ville</name><name sortKey="Salez, Nicolas" sort="Salez, Nicolas" uniqKey="Salez N" first="Nicolas" last="Salez">Nicolas Salez</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000210 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000210 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26387434
|texte= Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26387434" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeFranceV1
| This area was generated with Dilib version V0.6.35. |  |